December 27, 2019

December 27, 2019

Holidays

Cali Fair (Last week in December)


Halcyon Days (December 14-28)

Legal Holidays by Countries

Constitution DayNorth Korea
References in periodicals archive ?
He will be live in concert on December 27, 2019, at the newly launched state-of-the-art Coca Cola Arena in Dubai.
The FDA has informed us that the planned submission of this additional information constitutes a major amendment to the NDA, resulting in a three-month extension of the Prescription Drug User Fee Act (PDUFA) goal date to December 27, 2019 in order to provide time for a full review of the submission.
If the company's plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from June 30, 2019, or December 27, 2019, to regain compliance.
Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for lemborexant for use in the treatment of insomnia disorders for review in March 2019 and set a Prescription Drug User Fee Act (PDUFA) date for December 27, 2019. For Japan, a marketing authorization application for lemborexant for use in the treatment of insomnia disorder has been submitted to the Pharmaceuticals and Medical Devices Agency (PMDA) in March 2019 and is currently under review.
For example, during the run up to the December 27, 2019 referendum, suddenly, Ewe-based groups and organisations sprang up holding demonstrations, durbars, initiating court cases and sending petitions all over, and as far as to the United Nations, to stop Ghana from dividing what they claim was never its own.
As part of the Amendment, the lender received warrants to purchase 31.8 million common shares of the company at USD0.13 per share through December 27, 2019. For further details, please see the company's filing on Form 8-K dated, December 29, 2017.
On July 1, 2019 the Company announced the completion of the Euro 150 million first tranche and the start of a second tranche of Euro 200 million and to be completed by no later than December 27, 2019.
The Board of Directors has authorized a new share repurchase program for up to $100M of the Company's common stock through December 27, 2019. This is in addition to the Company's current $175M share repurchase authorization, expiring March 3, 2019, which had $93.1M remaining as of August 1, 2018.